Get the app!
Back to Trades
Sell4

BOSTON SCIENTIFIC CORP

BSX

Total Value
$7.6M
Net $5.0M sold
Sales
$5.0M
3 transactions

Company Information

Ticker Symbol
BSX
CIK
0000885725

Insider Information

Role
EVP & Group Pres, Cardiology
Officer
Location
MARLBOROUGH, MA

Filing Details

Filing Date
Nov 4, 2025
Transaction Date
Nov 3, 2025
Accession Number
0001225208-25-008911
Form Type
4
Net Trading Amount
-$5.0M

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Nov 3, 2025Common Stock50,000$26.15Exercise$1.3M
Nov 3, 2025Common Stock3,600$100.75Sale$362.7K
Nov 3, 2025Common Stock16,928$99.76Sale$1.7M
Nov 3, 2025Common Stock29,472$99.14Sale$2.9M

Derivative Transactions

DateSecuritySharesExercise PriceTypeValue
Nov 3, 2025Derivative50,000$26.15Exercise$1.3M

Footnotes

  1. (F1)The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.
  2. (F2)Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.72 to $100.80, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. (F3)Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $99.59 to $100.53, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. (F4)Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.57 to $99.54, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. (F5)The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
  6. (F6)Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.